Abstracts tagged "quality improvement and systemic lupus erythematosus (SLE)"

Abstract Number: 21 • 2017 Pediatric Rheumatology Symposium
Enhancing Quality of Care in Childhood-Onset Systemic Lupus Erythematosus by Improving Performance on Quality Indicator Measures in Cardiovascular and Bone Health
Emily A. Smitherman¹, Adam Furnier², Janalee Taylor³, Mary Beth Burns⁴, Hermine Brunner⁵ and Esi Morgan¹, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Rheumatology, PRCSG, Cincinnati, OH
Background/Purpose: Childhood-onset SLE (cSLE) leads to poor health outcomes, including cardiovascular and bone health, due to high rates of potentially devastating disease complications and medication…
Abstract Number: 1810 • 2014 ACR/ARHP Annual Meeting
Improper Use of Antinuclear Antibody (ANA) Test Can Result in Misdiagnosis, Increased Patient Anxiety, and Wasted Health Care Resources
Sahar Eivaz Mohammadi¹, Imam H Shaik¹, Parag Chevli¹, Fernando Gonzalez-Ibarra¹, Sohini Sarkar¹, Saurav Acharya¹, Prerna Dogra¹, Hesam Hekmatjou², Maushmi Savjani², Waheed Abdul² and Valentin Marian³, ¹Internal Medicine, Jersey City Medical Center-Barnabas Health, Jersey City, NJ, ²Internal Medicine, St. George's University SOM, St. George's, Grenada, ³Rheumatology, Jersey City Medical Center-Barnabas Health, Jersey City, NJ
Background/Purpose: Results of serologic tests for autoantibodies, including tests for Antinuclear antibodies (ANAs) and antibodies to specific nuclear antigens such as double-stranded DNA (dsDNA), play…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].